TECHNICAL FIELD
[0001] The invention relates to a mechanical assembly for dosing and delivering a fluid.
BACKGROUND OF THE INVENTION
[0002] Devices for dosing and delivering a fluid are widely used in consumer goods or in
pharmaceutical industry. Such devices for dosing and delivering a fluid should allow
a good control of the quantity of fluid dosed, as well as a good control of the delivery
of this fluid dose. In particular in the pharmaceutical industry, accurate control
of both the quantity and the delivery are critical. Furthermore, it is desired to
produce such devices in a reproducible and economical manner. It is the object of
this invention to provide accurate dosing and delivery of a fluid by means of an economical
dosing and delivery device.
[0003] In accordance with the invention, this object is accomplished in a dispensing device
for a fluid, the dispensing device comprising a reservoir, a shaft, a back seal, a
damper, a piston and a one-way valve, the back seal sealing a first end of the reservoir
and being displaceable along the shaft, the valve being on the second end of the reservoir,
the piston being fixed to one end of the shaft, the piston being located between the
valve and the damper, the damper being also fixed to the shaft, the damper being located
between the piston and the back seal, whereby the piston has an opened position and
a closed position, the open position allowing fluid communication between the valve
and the part of the reservoir between the piston and the back seal, the displacement
of the piston between the opened and the closed position being induced by a displacement
of the shaft along its own axis, the pressure in the area comprised between the valve
and the piston reducing when the piston is moved from its closed position towards
its opened position, the damper collapsing when the piston is moved from its closed
position towards its opened position, the only fluid flow from the part of the reservoir
situated between the damper and the back seal and the part of the reservoir situated
on the other side of the damper being a connecting passage situated in the damper
when the piston is moved from its opened position towards its closed position.
[0004] A device formed in accordance to the invention has a number of advantages. Since
the devices comprises a piston having an opened position and a closed position allowing
fluid communication between the valve and the reservoir, the quantity of fluid to
dispense can be accurately controlled by displacing the desired quantity of fluid
from the reservoir to the valve part by displacement of the piston from the closed
to the opened position, the absence of a direct link between the reservoir and the
valve avoiding uncontrolled emptying of the reservoir through the valve. Further,
as the pressure in the area comprised between the valve and the piston reduces when
the piston is moved from its closed position towards its opened position, the displacement
of the piston towards the opened position will necessitate the application of a force
threshold sufficient to overcome or at least to balance the pressure reduction and
internal system friction forces, so that undesired displacement of the piston is avoided.
The delivery of the dose is also accurately controlled via the combination of the
use of the one way valve, of the piston, of the damper and of the back seal. Indeed,
the one way valve will allow delivery of the fluid only when the piston is displaced
forward towards the valve, the speed of displacement of the piston being regulated
by the size of the connecting passage provided in the damper combined with the fluid
viscosity and applied mechanism force (e.g. spring force), thus allowing control on
the speed of the fluid delivery through the valve.
DETAILED DESCRIPTION OF THE INVENTION
[0005] The invention will now be described with reference to the accompanying drawings in
which:
[0006] Figure 1 is a plan cross section view illustrating a dispensing device in accordance
with the invention, the piston being in opened position.
[0007] Figure 2 is a plan cross section view illustrating a dispensing device in accordance
with the invention, the piston being in closed position.
[0008] The invention relates to a dispensing device 1 or 2 for a fluid 10. By fluid it should
be understood that it includes liquids having various viscosities. Preferred fluids
in a preferred embodiment of the invention are pharmaceutical fluids, but other applications
are envisaged, such as air-freshening devices for example.
The dispensing device 1 or 2 comprising a reservoir 11. The reservoir is typically
a chamber in which the fluid 10 is to be found. In a preferred embodiment, the reservoir
is substantially gas tight, thus avoiding or limiting chemical evolution due to contact
with O
2 or H
2O vapour for example, or to retain air out of the device, in order to avoid discrepancies
in the quantity of fluid to dose.
The dispensing device further comprises a shaft 12, the shaft typically being an elongated
element having as a main axis the more elongated direction, the shaft also normally
comprising a part having a constant cross section in a plane normal to the main axis
for allowing translation of a back seal 13, or being for example threaded to allow
helical displacement of the a back seal 13 along the shaft 12.
The device further comprises a back seal 13, the back seal 13 allowing sealing of
the reservoir 11, substantially independently from the quantity of fluid 10 contained
in the reservoir 11. This can be obtained for example by having a main part of the
reservoir 11 having a constant cross section in a plane perpendicular to the main
axis of the shaft 12, the back seal 13 having a substantially identical cross section,
the back seal 13 cross section being preferably marginally larger than the constant
cross section of the reservoir 11 in order to achieve sealing, so that displacement
of the back seal 13 along the shaft 12 allows to seal the reservoir 11 along the constant
cross section at any level in the main part of the reservoir 11 having the constant
cross section, thus allowing to seal in a gas tight manner a varying volume. In a
preferred embodiment, the back seal 13 is made of a flexible and resilient material
having an umbrella like shape, or even more preferably a double umbrella like shape,
such that the seal is constantly pressing against the reservoir 11 on the cross section
perimeter.
The device 1 or 2 further comprises a damper 14. The damper is preferably a part made
of a flexible material and having a umbrella like shape favouring collapsing during
displacement in one direction and damping during displacement in the other direction.
A piston 151 or 152 is also included in the device of the invention. The piston 151
or 152 is typically a part having a constant cross section being in a plane perpendicular
to its main axis, this piston 151 or 152 being elongated along the main axis, the
piston 151 or 152 being displaced in a part of the reservoir 11 which has a cross
section in a plane normal to the main axis of the piston 151 or 152 which is substantially
equal but preferably marginally smaller to the one of the piston 151 or 152 in order
to allow good sealing. Normally, the main axis of the piston 151 or 152 is parallel
of even aligned with the main axis of the shaft 12.
The device further comprises a one-way valve 16. By a one way valve it should be understood
that in normal use, the valve 16 will allow passage of the fluid in one direction
only. In a preferred embodiment, the valve 16 is a "self-seal" valve as described
for example in principle in EP-A-0 597 601, EP-A-0 395 380 or EP-A-0 160 336.
A necessary feature of the device of the invention is that the back seal 13 is sealing
a first end of the reservoir 11. This allows to use a gas tight reservoir 11, which
is useful to allow stability of the fluid product 10 and is necessary to the functioning
of the device as will be described below.
The back seal 13 should also be displaceable along the shaft 12, such displacement
including linear or helical displacement for example. The valve 16 is on the second
end of the reservoir 11. Indeed, the reservoir is normally elongated along the main
direction of the shaft, and comprises two end only, the first one being sealed by
the back seal 13 and the other comprising the valve 16.
The piston 151 or 152 is fixed to one end of the shaft 12. Indeed, the piston 151
or 152 is used in the device 1 or 2 according to the invention to push a dose 100
of product towards the valve 16. In order to achieve this, the piston 151 or 152 being
located between the valve 16 and the damper 14.
The damper 14 is also fixed to the shaft 12, the damper 14 being located between the
piston 151 or 152 and the back seal 13. Indeed, the damper 14 is located in the part
110 of the reservoir 11 which is not containing a dose 100 ready to be dispensed.
Indeed, the device 1 or 2 according to the invention is mainly intended for multiple
use, so that the damper 14 stands in the part of the reservoir 11 which contains a
plurality of doses which are not ready to be dispensed as they are not located between
the piston and the valve. It should be noted that the device 1 or 2 could also be
suitable for single use.
In order for the device of the invention to be functional, the piston 151 or 152 has
an opened position 151 and a closed position 152, the open position 151 allowing fluid
communication 153 between the valve 16 and the part of the reservoir 11 between the
piston 151 and the back seal 13. This fluid communication 153 allows a dose of product
100 to be placed in between the piston 151 and the valve 16 prior to dispensing.
The displacement of the piston between the opened 151 and the closed 152 position
is induced by a displacement of the shaft 12 along its own axis, which is the main
axis. The pressure in the area 100 comprised between the valve 16 and the piston reduces
when the piston is moved from its closed position 152 towards its opened position
151, thus generating a part vacuum. This allows to "suck in" a dose 100 of product
from the part of the reservoir 11 located between the piston an the back seal into
the part 100 between the valve and the piston when the piston goes in opened position
151.
The damper 14 collapses when the piston is moved from its closed position 152 towards
its opened position 151. This allows easing of the preparation for dispensing and
avoids excessive opposite forces when the operator actuates the device, whereby movement
or displacement of the piston from its closed position towards its opened position
will prepare for opening the fluid communication 153 between the part of the reservoir
between the piston and the back seal and the part 100 between the valve and the piston,
in order to fill this last part with fluid by means of the pressure reduction or part
vacuum mentioned above, the dose of fluid 100 being "sucked in" this part by the pressure
reduction through the fluid communication 153 being ready to be dispensed when pushed
by the piston through the valve.
As the only fluid flow from the part of the reservoir situated between the damper
and the back seal and the part of the reservoir situated on the other side of the
damper is a connecting passage 140 situated in the damper 14 when the piston is moved
from its opened position towards its closed position, such a move leading to delivery
of the fluid ready to be delivered is damped by the limitation on the fluid flow in
the connecting passage 140 situated in the damper 14. Indeed, for delivery of the
dose 100 situated between the piston and the valve 16, the piston has to move from
its opened 151 towards its closed 152 position, thus moving the damper 14 as both
the damper 14 and the piston are fixed to the shaft 12, the damper 14 moving through
the fluid 10, thus creating a non-equilibrium in the sealed reservoir 11 between the
part of the reservoir located between the damper 14 and the back seal 13 and the part
of the reservoir 11 located between the damper 14 and the piston, this non-equilibrium
being compensated by a flow in the connecting passage 140 situated in the damper 14,
thus controlling the speed of ejection or delivery of the dose 100 ready to be dispensed
through the valve 16 by control of the move of the piston. Indeed, the piston will
have a maximum speed depending marginally on the compressibility and mainly on the
viscosity of the fluid and on the geometrical and/or mechanical characteristics of
the device. Indeed, for example, the larger the connecting passage 140 or the higher
the applied forward force to the shaft 12 the higher the maximum speed.
[0009] In a preferred embodiment, the shaft is made out of a material conducting electricity,
such as metal for example. Indeed, in a more preferred embodiment, the fluid is electrically
charged prior to being dispensed. The device according to the invention is particularly
suited for this application as charging of the fluid will be facilitated by the control
on the flow. In particular, there is a maximum speed beyond which charging the fluid
becomes difficult or impossible, so that a damped delivery allows good charging. Preferably,
the charge rate is matched to the fluid flow rate to achieve efficient electro-hydrodynamic
atomisation of the fluid.
[0010] In a preferred embodiment, the volume comprised between the piston in the opened
position and the valve is of less than 100 µL.
[0011] In another preferred embodiment, the control on delivery is such that the volume
of fluid dispensed at each dispensing operation varies of less than 10% between each
dispensing operation. Even more preferably, the variation is of less than 5%.
[0012] In a further preferred embodiment, a compressed spring is located on the end of the
shaft opposite to the one to which the piston is fixed, applying a force onto the
shaft in a direction substantially parallel to the shaft axis.
[0013] In an additional preferred embodiment, the connecting passage is a single opening
provided in the damper, even more preferably a circular opening.
[0014] A most preferred embodiment of the invention is obtained by integrating the device
of the invention to the spray device as disclosed in the pending applications GB9806937.0
and GB9806939.6.
Such a spray device is particularly suited for treatment of maladies affecting the
nasal region, such as hay fever or congestion due to colds. Recently it has been recognised
that the mucous membranes of the nasal cavity can be used as a convenient delivery
site for drugs' targeted at other areas of the body. See for example WO 92/11049 which
discloses a pen shaped device for nasal administration of, particularly, insulin.
A spray form is often convenient for such treatments. Treatment of the eyes can also
conveniently be effected by a spray device. Preferred volume doses for such applications
are generally low, down to less than 10 µl. Typically, repeat dosing will be required
in order to make a treatment fully effective. Achieving clean stop-start flow from
spray devices delivering such low volumes can be difficult. Typical problems encountered
include residual weeping from a valve after application, with the potential for back
contamination, and valve clogging.
Use of an elastomeric valve, particularly a slit valve, provides clean stop-start
flow without clogging, particularly by the combination of the valve (clean start)
and sudden pressure reduction via pressure relief area (clean stop), even if the sprayed
fluid comprises a finely divided particulate solid.
Preferably, the spray device is adapted to provide one or more unit doses of a fluid,
each dose having a volume in the range from about 1 to about 100 µl, the device comprising
an elastomeric, self-sealing valve having a fluid side and a delivery side, the valve
opening to allow passage of the fluid when pressure is applied to fluid on the fluid
side and sealing when the pressure is removed.
Preferably the spray device is an electrostatic spray device which charges the spray
before entry into the nostrils.
Fluids
[0015] The device of the invention preferably comprises a fluid reservoir containing a pharmaceutically
acceptable fluid, the fluid comprising a pharmaceutically acceptable treatment agent
selected from medicaments, flavours, salts, surfactants and mixtures thereof. The
fluid optionally comprises other adjuvants dissolved or dispersed within it. The fluid
can be aqueous or non-aqueous. Suitable aqueous fluids include water and mixtures
of water with water-miscible solvents such as glycerol, propylene glycol, or alcohols
such as ethanol or isopropyl alcohol. Aqueous emulsions can also be used, either water-in-oil
or oil-in water emulsions. Preferably the fluid is an aqueous solution, dispersion
or oil-in-water emulsion. Suitable non-aqueous fluids comprise polyethylene glycols,
glycerol, propylene glycol, dimethyl isosorbide, silicone oils, ketones, ethers and
mixtures thereof.
Although not limited to any particular range of resistivity, the invention has particular
application to low resistivity fluids, especially those having a bulk resistivity
of less than 1 x 10
8 ohm.cm, preferably those having a resistivity of less than 1 x 10
4 ohm.cm, more preferably less than 1 x 10
3 ohm.cm. If necessary, the fluid may comprise a resistivity modifier, such as a pharmaceutically
acceptable salt, in order to bring the bulk resistivity within the required range.
The fluid is preferably a pharmaceutically acceptable intranasal carrier. Preferably,
the nasal composition is isotonic, i.e., it has the same osmotic pressure as blood
and lacrimal fluid. The desired isotonicity of the compositions of this invention
may be accomplished using, for example, the sodium chloride already present, or other
pharmaceutically-acceptable agents such as dextrose, boric acid, citric acid, sodium
tartrate, sodium citrate, sodium phosphate, potassium phosphate, propylene glycol
or other inorganic or organic solutes. Sodium chloride is preferred particularly for
buffers containing sodium ions. Further examples of sodium chloride equivalents are
disclosed in
Remington's Pharmaceutical Sciences pp. 1491-1497 (Alfonso Gennaro 18th ed. 1990), which is herein incorporated by reference.
Medicaments
[0016] The fluid can comprise a wide range of medicaments. By "medicament" is meant a drug
or other substance intended to have a therapeutic effect on the body. Suitable levels
of the medicament are from 0.001 to 20%, preferably from 0.01 to 5%, more preferably
from 0.1 to 5%. It will be appreciated that the levels of specific medicaments will
depend on many factors including their potency, safety profile, solubility / ease
of dispersion and intended effect. The medicament, when used, can be one which is
intended to have an effect at the site of application, such as a decongestant, antihistamine
or anti-inflammatory drug, or it may be intended for systemic absorption such as an
antiviral, anti-depressant, anti-emetic, anti-pyretic medicament or a hormone or such-like.
The medicament can be soluble in the fluid or can be an insoluble, finely divided
particulate liquid or solid dispersed within the fluid.
Suitable decongestants include oxymetazoline, tramazoline, xylometazoline, naphazoline,
tetrahydrazoline, pseudoephedrine, ephedrine, phenylephrine, their pharmaceutically
acceptable salts, such as the hydrochlorides, and mixtures thereof. Preferred decongestants
are selected from oxymetazoline, xylometazoline, their pharmaceutically acceptable
salts and mixtures thereof. Especially preferred for use herein is oxymetazoline hydrochloride
which is soluble in water. When used in the compositions of the present invention,
the decongestant is preferably present at a concentration of from about 0.01% to about
3.0%, more preferably from about 0.01% to about 1 %.
Antihistamines useful to the present invention include, but are not limited to, fast-acting,
histamine H-1 receptor antagonists. Such H-1 receptor antihistamines may be selected
from among the following groups of antihistamines: alkylamines, ethanolamines, ethylenediamines,
piperazines, phenothiazines, piperidines. Examples of useful fast acting antihistamines
include acrivastine, carbinoxamine, diphenhydramine, chloropheniramine, brompheniramine,
dexchloropheniramine, doxylamine, clemastine, promethazine, trimeprazine, methdilazine,
hydroxyzine, pyrilamine, tripelennamine, meclizine, triprolidine, azatadine, cyproheptadine,
rocastine, phenindamine or pharmaceutically acceptable salts and mixtures thereof.
Other useful antihistamines include terfenadine, azelastine, cetirizine, astemizole,
ebastine, ketotifen, lodoxamide, loratadine, levocabastine, mequitazine, oxatomide,
setastine, tazifylline, temelastine or pharmaceutically acceptable salts and mixtures
thereof. When used in the compositions of the present invention, the antihistamine
component is preferably present at a concentration of from about 0.01% to about 3.0%,
more preferably from about 0.01% to about 1%.
The medicament can also be an anti-inflammatory agent such as a corticosteroid. Particularly
preferred agents within this class are glucocorticoids selected from the group consisting
of beclomethasone, flunisolide, fluticasone, memetasone, budesonide, pharmaceutically
acceptable salts thereof and mixtures thereof. When used in the compositions of the
present invention, the anti-inflammatory agent is preferably present at a concentration
of from about 0.001% to about 0.1%, more preferably from about 0.01% to about 0.1%.
Also useful herein are xanthine derivatives such as caffeine and methylxanthine and
the like; antiallergics; mucolytics; anticholinergics; non-opiate analgesics such
as acetaminophen, acetylsalicylic acid, ibuprofen, etodolac, fenbuprofen, fenoprofen,
ketorolac, flurbiprofen, indomethacin, ketoprofen, naproxen, pharmaceutically acceptable
salts thereof and mixtures thereof; opiate analgesics such as butorphanol; leukotriene
receptor antagonists; mast cell stabilisers such as cromolyn sodium, nedocromil and
lodoxamide; lipoxygenase inhibiting compounds; and nicotin, insulin and calcinotin.
Further examples of suitable medicaments can be found in WO97/46243, EP-A-780127,
US-A-5,124,315, US-A-5,622,724, US-A-5,656,255 and US-A-5,705,490
Flavours
[0017] Various flavouring and/or aromatic components (e.g., aldehydes and esters) can be
used in the fluids of the invention. These include, for example, menthol, camphor,
eucalyptol, benzaldehyde (cherry, almond); citral (lemon, lime); neral; decanal (orange,
lemon); aldehyde C-8, aldehyde C-9 and aldehyde C-12 (citrus fruits); tolyl aldehyde
(cherry, almond); 2,6-dimethyl-octanal (green fruit); 2-dodecenal (citrus, mandarin);
and herbal components such as thyme, rosemary and sage oils. Additional aromatic components
suitable for use in the present invention include those described in
U.S. Patent 4,136,163 to Watson et al.,
U.S. Patent 4,459,425 to Amano et al., and
U.S. Patent 4.230,688 to Rowsell et al.; all of which are herein incorporated by reference. Mixtures of
these aromatics can also be used.
Surfactants
[0018] The fluid can also comprise one or more pharmaceutically acceptable surfactants.
Such surfactants can be useful for dispersing or emulsifying medicaments or flavours,
for enhancing absorption across the nasal membrane or as treatment agents in their
own right, such as for softening earwax. The surfactants can be anionic, nonionic,
cationic or amphoteric, preferably they are nonionic. Typical nonionic surfactants
useful herein include: polyoxyethylene derivatives of fatty acid partial esters of
sorbitol anhydrides such as polysorbate 80; polyoxyethylene derivatives of fatty acids
such as polyoxyethylene 50 stearate, as well as oxyethylated tertiary octyl phenol
formaldehyde polymer (available from Sterling Organics as Tyloxapol) or mixtures thereof.
The usual concentration is from 0.1 % to 3% by weight.
Salts
[0019] The fluid can also comprise one or more pharmaceutically acceptable salts. The salt
can mineral salts such as e.g. sodium chloride, or salts of organic acids such as
sodium citrate.
Other adjuvants
[0020] The fluid can further comprise other ingredients such as thickeners, humectants,
suspending aids, encapsulating aids, chelating agents and preservatives.
The viscosity of the compositions may be maintained at a selected level using a pharmaceutically-acceptable
thickening agent. Suitable thickening agents include, for example, xanthan gum, methyl
cellulose, microcrystalline cellulose, carboxymethyl cellulose, chitosan, hydroxypropyl
cellulose, hydroxypropyl methyl cellulose, hydroxymethyl cellulose, hydroxyethyl cellulose,
carboxyvinyl polymer, carbomer, and the like or pharmaceutically acceptable salts
thereof. Mixtures of such thickening agents may also be used. The preferred concentration
of the thickener will depend upon the agent selected. The important point is to use
an amount which will achieve the selected viscosity. Viscous compositions are normally
prepared from solutions by the addition of such thickening agents.
Fluids useful in the present invention can also comprise from about 0.01% to about
5% of a humectant to inhibit drying of the mucous membrane and to prevent irritation.
Any of a variety of pharmaceutically-acceptable humectants can be employed including,
for example sorbitol, propylene glycol, polyethylene glycol, glycerol or mixtures
thereof. As with the thickeners, the concentration will vary with the selected agent,
although the presence or absence of these agents, or their concentration is not an
essential feature of the invention.
A pharmaceutically-acceptable preservative is generally employed to increase the shelf
life of the compositions of the present invention. A variety of preservatives including,
for example, benzyl alcohol, parabens, phenylethyl alcohol, thimerosal, chlorobutanol,
chlorhexidine gluconate, or benzalkonium chloride can be employed. The most preferred
preservative system for use herein comprises a combination of benzalkonium chloride,
chlorhexidine gluconate and disodium EDTA as a chelating agent. A suitable concentration
of the preservative will be from 0.001% to 2% based on the total weight, although
there may be appreciable variation depending upon the agent selected.
[0021] The device is adapted to provide one or more unit fluid doses, preferably multiple
fluid doses, each preferably with a volume in the range of from about 1 to about 100
µl, more preferably from about 1 to about 20, more preferably from about 5 to about
15 µl. The dose volume is preferably pre-set but may be adjusted by the user to a
desired volume. Preferably, the device is a refill unit which may be part of a larger
device and which may be changed or replaced.
The device is preferably adapted to produce a spray having a fluid ligament, the ligament
extending from the nosepiece and having a nosepiece end and a delivery end, the spray
further comprising a spray cone diverging from the delivery end of the ligament. By
"nosepiece end" is meant the point at which a plane (hereinafter the nosepiece plane)
drawn perpendicular to the axis of the ligament and just touching the exterior of
the nosepiece would intersect the centre of the ligament. The ligament preferably
has a length of from about 1 to about 20 mm, more preferably from about 1 to about
10 mm, yet more preferably from about 2 to about 8 mm, and especially from about 3
to about 6mm from the nosepiece end to the delivery end.
In preferred embodiments the spray cone has a cone angle of from about 10 to about
90°, preferably 20 to about 50°, more preferably from about 30 to about 40°. In electrostatic
devices, the length of the ligament and the spray cone angle can be adjusted by varying
the viscosity or surface tension of the fluid, by varying the fluid flow rate or exit
velocity, or by changing the valve slit characteristics or valve material properties,
or by varying the electrical field strength through applied voltage, potential gradient
or by use of a field intensifying electrode.
The total length of the ligament can be, and preferably is, longer than the length
from the nosepiece end to the delivery end since the ligament preferably originates
from a point on the device side of the nosepiece plane, such as from an elastomeric,
self-sealing valve as disclosed herein, and passes through a passage in the nosepiece.
Suitably the distance from the point of origin of the ligament to the nosepiece plane
is in the range from about 2 mm to about 15 mm, preferably from about 3 to about 10
mm and more preferably from about 5 to about 9 mm. In this way the nosepiece can be
employed as a field intensifier which helps to control the ligament length. For this
purpose the nosepiece is preferably a non-conducting material such as a plastic which
can be e.g. polypropylene but is preferably a soft thermoplastic elastomer which provides
for greater comfort if held against the nose. Elastomers described herein for the
self-sealing valve are also suitable for the nosepiece.
Electrostatic devices suitable for ligament mode spraying are described in WO 96/40441,
in EP-A-501,725 and in co-pending application PCT/GB97/02746. Preferably the present
device is a device according to embodiments of EP-A-501,725 or PCT/GB97/02746 in which
a jet is created by mechanical means and an applied high voltage leads to the jet
or ligament breaking up into a spray cone. Suitable jet velocities are from about
0.5 to about 8, preferably from about 1 to about 3 ms
-1.
A suitable high voltage is in the range from about 1 kV up to about 15 kV, preferably
from about 2kV to about 10kV and more preferably from about 2kV to about 5kV. The
voltage can conveniently be applied, even within the constraints of a small hand-held
device, from a low voltage (1.5V is sufficient) battery coupled to a step-up transformer.
The battery is preferably of the long-life type and can be rechargeable. The generator
can be activated by the user by means of an external switch which can also be used
to mechanically prime the pump. Preferably the switch includes a metal portion by
means of which the user completes an earth return path to the high voltage circuit.
A suitable arrangement for the overall device construction is described in PCT/GB97/02746.
In this way the user does not acquire a net charge. Alternate arrangements, whereby
an alternating voltage is applied, can also be used to prevent charge build-up.
The device is preferably activated to deliver the spray. The ligament of the spray
extends through the nostril opening, into the vestibule and preferably to within a
short distance of the nasal valve opening, before breaking up to form the spray cone.
In order to provide clean cut-off at low unit volumes the device preferably comprises
an elastomeric, self-sealing exit valve having a fluid side and a delivery side, the
valve opening to allow passage of the fluid when pressure is applied to fluid on the
fluid side and sealing when the pressure is removed. Preferably, clean stop is achieved
by having the piston ending its forward movement in a pressure relief chamber (wider
diameter area) resulting in a immediate pressure drop and resulting valve closure.
By "exit valve" is meant that the elastomeric valve is the final dispensing valve
and that there are no other elements of the device which mechanically, restrict or
modify the flow of the fluid on the downstream side of the valve. In highly preferred
embodiments herein the valve is a slit valve. The valve can comprise a single slit
or tow or more intersecting slits, to form a cross shape for example. Preferably,
however, the valve comprises a single slit. Although the valve can be flat it is preferably
dome-shaped by which is meant a nonplanar valve having a recess such as with a hemispherical
or frustoconical dome. In preferred embodiments the valve is essentially in the form
of a hemispherical dome having a flange along its perimeter so that a collar can be
fitted to retain the valve in the device. The diameter of the valve, including the
flange, is typically from about 2 to about 6 mm with the dome portion having a diameter
of from about 1 to about 4 mm, typically about 2.5mm and a thickness from inside to
out of from about 0.5 to about 1.5 mm, suitably about 1 mm. The valve need not be
of uniform thickness. In preferred embodiments the valve dome's exterior surface is
hemispherical whereas the internal surface is formed with a small flat at the top
of the dome where the slit is formed. Suitable slit widths are from about 50 to about
400 µm, preferably from about 150 to about 250 µm. It is to be understood that the
slit width refers to the longest dimension of the slit when first created. The term
"elastomer" herein refers to a material which is both elastically compressible and
elastically extensible. A wide range of elastomers can be used, including but not
limited to polyurethanes; chloroprene, butyl, butadiene and styrene-butadiene rubbers,
and silicone elastomers such as 2 part room temperature vulcanising (RTV) silicones.
Preferred for use herein are the 2 part silicone RTVs. Suitable silicone RTVs are
available under the trademark NuSil and have a hardness of from about 30 to about
80 Shore A, preferably from about 40 to about 70 Shore A. The elastomers can optionally
be mixed with a suitable plasticiser or foaming agent to make them more compressible.
The elastomer may also have other materials dispersed within it in order to modify
its properties, such as its conductivity. If elastomers of low tear strength are employed,
the slit width may grow if the slit is held open for a prolonged period of time. The
slit valve can be formed by piercing an injection or compression moulded elastomeric
seal, of the same dimensions and shape as the intended valve, with a pin having a
sharpened tip. The slit width is roughly proportional to the pin width. The pin can
be a flat blade or can have a polygonal or round cross-section. The pin preferably
has a polygonal or, especially, a round cross-section. It has been found that cone-shaped
sharp-edged pins create a cut which behaves in use as a flap rather than a hole. This
can lead to a jet which is not straight or even to the creation of two or more jets
which may lead to unreliable or unpredictable spraying. Suitable pin diameters are
from about 100 to 350, more preferably from 150 to 250 µm in diameter. When silicone
elastomers are used it is preferred that the piercing pin is withdrawn rapidly after
forming the slit to avoid undesired slit growth. It has further been found that the
geometry of the elastomeric seal and the method of piercing have a significant effect
on the effectiveness and reproducibility of slit formation. More reliable slit formation
is obtained if the seal is pierced from the inside of the dome rather than from the
outside.
The valve normally opens when pressure is applied to fluid on the fluid side and seals
when the pressure is removed. The applied pressure is suitably in the range from about
200 to about 5000 mbar (20 to 500 kPa), preferably from about 500 to about 3000 mbar
(50 to 300 kPa).
The flow rate through the valve is generally proportional to the pressure applied
and is suitably in the range from about 5 to about 50, more preferably from about
5 to about 30 µls
-1. At such pressures and with the disclosed valve type and slit dimensions a straight
fluid ligament with an exit velocity of from about 0.5 to about 8 preferably from
about 1 to about 3 ms
-1 is obtained.
The diameter of the issuing ligament is partly determined by the flow rate and is
generally less than the width of the slit valve. Depending on the flow rate, ligament
diameters of less than 50 µm can be achieved, even when a valve slit width of 200
µm is employed. The ligament diameter strongly influences the particle size of the
spray after break-up into the spray cone, the particle size being broadly similar
to the ligament diameter. It is a feature of the ligament mode electrostatic spraying
herein that a tightly distributed, almost mono-disperse spray is obtained. It is thus
possible to achieve a spray with a median droplet size of from 20 to about 80, preferably
from about 30 to about 70 µm, more preferably from about 40 to about 60 µm, the particle
size distribution generally having a standard deviation of less than 5, typically
less than 2 µm, and preferably less than 1 µm. It is commonly understood that, for
nasal spraying, a particle size of 10 µm or less is undesirable so that the particles
are not carried through into the lungs. It is believed, however, that having an electrostatic
charge on the spray particles makes them much less likely to be carried beyond the
nose since the charged particles tend to find an earthed surface rather quickly.
The clean stop performance of the tip valve can be further improved by introducing
a pressure relief feature behind the valve. This area will provide a sudden pressure
drop when the piston enters this area near completing its forward stroke and enforce
immediate and secure closure of the valve with no dripping at the end of the full
dose.
Methods
[0022] The spray device herein is suitable for spraying into a body cavity, particularly
into the nose, mouth or ears of a human. The low volume and gentle spray also make
it suitable for e.g. ophthalmic spraying. Preferably the device is a nasal spray device.
A preferred method of administering a fluid to the nasal cavity from the spray device
comprises spraying the fluid into the nasal cavity without substantial penetration
of the device into the nostrils. By "without substantial penetration into the nostrils"
herein is meant that there is no insertion of a nozzle or such-like into the nasal
vestibule. In use, the nosepiece of the device is preferably placed in contact with
the nostril opening to obtain the full benefit of the field intensifying effect described
herein in relation to the nosepiece. If pressure is applied by the user, for certainty
of contact or to assist in orientation there may be some flaring of the nostril or
overlap with the septum cartilage but nevertheless the nosepiece will not be completely
surrounded by the nostril.